Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

Trial Profile

Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Pitolisant (Primary)
  • Indications Hypersomnia
  • Focus Therapeutic Use
  • Acronyms HAROSA IV
  • Sponsors Bioprojet
  • Most Recent Events

    • 22 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 22 Nov 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2017.
    • 22 Nov 2017 Planned initiation date changed from 1 Jan 2017 to NULL.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top